PROKIDNEY CORP. (PROK) Form 8-K — May 15, 2026

$PROKForm 8-KItems 2.02, 7.01, 8.01, 9.01Filed May 15, 2026, 11:49 AM ET0001193125-26-225848Original filing

ProKidney Corp. reported Q1 2026 financial results, ending the quarter with $224.9 million in cash and marketable securities, sufficient to fund operations into mid-2027. The company recorded a net loss of $42.6 million before noncontrolling interest, driven by increased R&D spending of $33.8 million as it scales its pivotal Phase 3 PROACT 1 trial. The filing highlights significant clinical progress, noting that enrollment for the accelerated approval analysis of rilparencel is on track to complete in mid-2026.

Key figures

Revenue: 226000
Cash Position: 224900000
Shares Outstanding: 301953977
Ga expenses q1 2025: 14400000
Ga expenses q1 2026: 11300000
Rd expenses q1 2025: 27300000
Rd expenses q1 2026: 33800000
Cash position dec 2025: 270000000
Weighted avg shares class a: 141925099

Price after filing

1 day: 0.0%7 days: +2.3%30 days: -2.9%

Close on the filing date to close N calendar days later (from $1.71). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.